Filing Details

Accession Number:
0001171843-15-000934
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-02-19 16:05:44
Reporting Period:
2015-02-18
Filing Date:
2015-02-19
Accepted Time:
2015-02-19 16:05:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
3116 Akorn Inc AKRX Pharmaceutical Preparations (2834) 720717400
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1234712 Joseph Bonaccorsi 1925 West Field Court Suite 300
Lake Forest IL 60045
Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-02-18 7,500 $1.46 319,189 No 4 M Direct
Common Stock Acquisiton 2015-02-18 92,500 $1.46 411,689 No 4 M Direct
Common Stock Disposition 2015-02-18 40,827 $47.33 370,862 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-02-18 7,500 $0.00 7,500 $1.46
Common Stock Stock Option (right to buy) Disposition 2015-02-18 92,500 $0.00 92,500 $1.46
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
92,500 2015-02-22 No 4 M Direct
0 2015-02-22 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2014.
  2. Upon execution of transactions disclosed on this Form 4, all securities subject to the 10b5-1 trading plan have been transacted and the plan has expired pursuant to its terms.
  3. All proceeds from the sale were used to cover exercise price and taxes due upon exercise of options.
  4. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $46.80 to $48.49 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at separate prices within the foregoing range.
  5. Amount of Shares Beneficially Owned Following Reported Transaction includes 104,414 unvested shares subject to a restricted stock awards and 266,448 shares owned outright. Shares owned outright include 1,015 shares acquired through participation in the Employee Stock Purchase Plan for the 2014 plan year.
  6. The option vested in three annual installments with 33,333 options vesting on each of February 22, 2011 and February 22, 2012, and 33,334 options vesting on February 22, 2013.
  7. Exercise of stock options that were approaching their 5-year expiration date.
  8. There was no consideration given in exchange for the security.